Expert Interviews

Key adverse events from the TRuE-V studies are highlighted.

Dr. Rosmarin discusses the efficacy data from the TRuE-V long-term extension study.

A medical expert highlights a new FDA-approved medication as a key treatment in Demodex blepharitis.

The study design for the TRuE-V long-term extension study is discussed.

Therapies such as tee tree oil and other OTC agents are evaluated in the management of Demodex blepharitis.

The key safety and efficacy data of the TRuE-V studies are discussed.

Dr Starr provides considerations for navigating diagnostic challenges related to Demodex blepharitis.

Chesahna Kindred, M.D., MBA, FAAD, reviews the vitiligo support groups recommended for patients.

Renata Block, PA-C, and Gary M. Owens, M.D., explore the access considerations for patients with vitiligo in special populations and review resources that clinicians and payers can share with patients with vitiligo.

Chesahna Kindred, M.D., MBA, FAAD, examines how treatment can affect the quality of life in patients with vitiligo.

Drs. Owens and Rosmarin discuss an overview of the TRuE-V studies and unmet needs in vitiligo.

Symptoms non-unique to DB, such as itching and scratching, may lead to misdiagnosis.

Gary M. Owens, M.D., explains how an organization weighs the potential clinical outcomes for patients versus the cost of novel therapies for vitiligo.

Renata Block, PA-C, and Chesahna Kindred, M.D., MBA, FAAD, explain how organizations addresses barriers to medication access (co-pay cards, patient coordinators) for novel vitiligo therapies.

Discussion on how payers and providers collaborate to enhance patient care and cost management. The upcoming entry of biosimilars post-2023 and their potential influence is also covered.

Gary M. Owens, M.D., and Chesahna Kindred, M.D., MBA, FAAD, discuss how an optimal multidisciplinary care model for patients with vitiligo can be achieved among providers, pharmacists and payers.

Dr Starr addresses long-term consequences associated with nontreatment of Demodex blepharitis.

Experts review the main side effects of ruxolitinib, how to monitor for them in your practice, and the key takeaways for clinicians and payers to know about the two phase 3 trials that led to the approval of ruxolitinib in vitiligo.

Challenges with biosimilars and unbranded biologics are discussed and how can they be improved.

Gary M. Owens, M.D., explains how ruxolitinib fits into the treatment pathway for patients with vitiligo from a payer perspective.

Christopher Starr, MD, FACS, highlights ways Demodex blepharitis can impact quality of life for affected patients.

Experts review which patients with vitiligo they would consider using ruxolitinib in.

An overview of how benefit channels, such as pharmacy benefit and medical benefit, differ and how it impacts utilization of biosimilars and unbranded biologics.

Overview of bias toward patients with C. Difficile, plus an overview of commercial insurances vs Medicare in treatment of C. Difficile.

Chesahna Kindred, M.D., MBA, FAAD, and Renata Block, PA-C, describe how ruxolitinib works differently from other topicals traditionally used in the treatment of vitiligo.

Experts review the benefits and side effects of off-label treatments for patients with vitiligo such as corticosteroids, tacrolimus, pimecrolimus or calcipotriene (in combination with corticosteroids).

How an open marketplace impacts future competition, pricing transparency, and formulary management.

As more therapeutic options become available, individualizing treatment for hemophilia A becomes increasingly important.

The potential benefits and uncertainties surrounding gene therapy include its curative potential, the need for immunosuppression, ongoing care needs, and a lack of long-term data.